About Elizabeth Hughes, MD

Research Affiliation

2025-Present
Principal Investigator, The Clinical Trials Network

2006-2024
Principal Investigator,  Clinical Trials of Texas (now Flourish Research)

Research Experience

2023-2025: Cara Therapeutics: A two part, multi center, randomized, double-blind study to evaluate the efficacy and safety of study drug as adjunct therapy to a topical corticosteroid for moderate to severe pruritus in adult subjects with atopic dermatitis

2023-2025: Aslan Pharmaceuticals: a randomized double blind placebo controlled multicenter, dose ranging trial to evaluate the efficacy and safety of study drug in adult patients with moderate to severe atopic dermatitis

2016-2020: A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Of “Study Drug” Administered By Intravenous Infusion In Subjects With Psoriasis (CTI-000675)

2016-2020: A Phase 3 Multi-Center, Open Label Study Evaluating The Long Term Safety Of “Study Drug” Once Daily In The Treatment Of Acne Vulgaris (CTI-000685)

2016-2020: A Phase 3 Multi-Center, Randomized, Double-Blinded, Vehicle-Controlled, Parallel Group Study Comparing The Efficacy, Tolerability And Safety Of “Study Drug” And Vehicle Gel Once Daily In The Treatment Of Acne Vulgaris (CTI-000659)

2016-2020: A Phase 2a, Open-Label, Multicenter, Activity And Safety Study Of “Study Drug” Ointment 1% In Subjects With Actinic Keratosis On The Face Or Scalp (CTI-000679)

2016-2020: “Study Drug” Versus “Study Drug” And Placebo Comparators In A Randomized Double Blind Trlal For Maintenance Use In Moderate To Severe Plaque Type Psoriasis (UltlMMa-1) (CTI-000656)

2015-2020: A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle -Controlled, 2-Arm, Parallel Group Comparison Study Comparing The Efficacy And Safety Of “Study Drug” And “Study Drug” Vehicle Lotion In The Treatment Of Acne Vulgaris (CTI-000640)

2015-2020: A Multicenter, Randomized, Double-Blind Study Comparing The Efficacy And Safety Of “Study Drug” Dosing Regimens In Patients With Moderate-to-Severe Plaque Psoriasis (CTI-000611)

2015-2020: A Randomized, Double-Blind, Multicenter Study To Evaluate Efficacy, Safety, and lmmunogenicity Of An “Study Drug” And “Study Drug” In Subjects With Moderate To Severe Chronic Plaque-Type Psoriasis (CTI-000618)

2014-2020: A Multicenter, Randomized, Double Blind, Parallel Group, Vehicle Controlled Study Of The Safety And Efficacy Of “Study Drug” 3 Mcg/G Ointment Applied Twice Daily For 8 Weeks In Pediatric Subjects (2 To 12 Years Of Age) With Mild To Moderate Plaque Psoriasis (CTI-000495)

2014-2016: Effect Of “Study Drug” Plus “Study Drug” Gel (“Study Drug”) On The HPA Axis And Calcium Metabolism In Adolescent Subjects (Aged 12 To 16 Years, 11 Months) With Scalp And Body Psoriasis (CTT- 000453) 

2014-2016: A 52-week, Multicenter, Randomized, Double-Blind Study Of “Study Drug” To Demonstrate Efficacy As Assessed By Psoriasis Area And Severity Index At 16 Weeks Of Treatment Compared To “Study Drug” And To Assess Long-Term Safety, Tolerability And Efficacy In Subjects With Moderate To Severe Plaque Psoriasis (CTI- 000474)

2014-2015: A Phase Ill 2 Arms, Multicenter, Randomised, Double-Blind Study To Assess The Efficacy And Safety Of “Study Drug” 1% Cream Applied Twice Daily For 5 Days Versus Placebo In The Treatment Of Patients With Impetigo (CTT-000523)

2014-2015: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate Three Doses Of “Study Drug” In The Treatment Of Moderate To Very Severe Glabellar Lines (CTT-000485)

2014-2015: A Randomized, Double-Blind, Placebo And Positive Controlled, Single And Multiple Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of “Study Drug” In Chronic Plaque­ Type Psoriasis Patients (CTT-000480)

2014-2015t: A Randomized, Vehicle-Controlled, Double-Blind, Parallel Group, Multi-Center Phase Ill Study To Evaluate The Safety And Efficacy Of “Study Drug” In Subjects With Plaque Psoriasis (CTT-000467)

2014-2015: A Pharmacokinetic Study To Determine The Systemic Exposure In “Study Drug” 0.1% Topical Gel During Dermal Application Under Maximal Use Conditions For 4 Weeks In Adolescent And Adult Subjects With Acne Vulgaris (CTT-000498)

2013-2016: Pharmacokinetics And Pharmacodynamics Of “Study Drug” 3 Mcg/G Ointment Applied Twice Daily For 14 Days Under Conditions Of Maximal Use In Pediatric Subjects (2 To 12 Years Of Age) With Plaque Psoriasis (CTT-000405)

2013-2015: Safety And Efficacy Of Escalating Doses Of Two “Study Drug” Formulations Applied Once Daily For Two Consecutive Days On Full Face Or Approximately 250 cm {40in) On The Chest In Subjects With Actinic Keratosis (CTT-000438)

2013-2014: A Phase 2, Randomized, Double-Blind, Vehicle Controlled, Dose-Ranging Study Of The Effect Of “Study Drug” In Subjects With Axillary Hyperhidrosis (CTT-000448)

2013-2014: A Pharmacokinetic Study To Determine The Systemic Exposure To “Study Drug” During Dermal Application Of Either A Fixed-Dose Combination Of “Study Drug” 3%/ “Study Drug” 2.5% Gel Or “Study Drug” 0.3% Gel For 4 Weeks In Adolescent And Adult Subjects With Acne Vulgaris (CTT-000410)

2013-2013: Relative Bioavailability Of “Study Drug” 50 mg/ml Administered Subcutaneously By A Disposable “Study Device” Compared With Intramuscular Administration Of The United States-Reference Listed Drug “Study Drug” In Patients With Psoriasis (CTT-000415)

2013-2013: “Study Drug” Compared To Vehicle In Subjects With Psoriasis Vulgaris (CTT-000423)

2012-Present: A 64-Week, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Design Study To Evaluate The Efficacy And Safety/Tolerability Of “Study Drug”, Followed By An Optional Long-Term Safety Extension Study, In Subjects With Moderate-To-Severe Chronic Plaque Psoriasis (CTT-000391)

2012-Present: A Multicenter, Double-Blind, Randomized Withdrawal Extension Study Of “Study Drug” In Prefilled Syringes To Demonstrate Long-Term Efficacy, Safety And Tolerability Up To 2 Years In Subjects With Moderate To Severe Chronic Plaque-Type Psoriasis Completing Preceding Psoriasis Phase Ill Studies With Secukinumab (CTT-000369)

2012-Present: A Multicenter, Double-Blind And Open Label, 2 Year Extension Study Of “Study Drug” In Prefilled Syringes, Assessing Long-Term Safety, Tolerability And Efficacy In Subjects With Moderate To Severe Chronic Plaque-Type Psoriasis Treated With Either A Fixed Dose Regimen Or On A Retreatment At Start Of Relapse Regimen (CTT-000378)

2012-2014: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Study To Evaluate The Efficacy, Safety, And Pharmacokinetics Of “Study Drug In Adult Subjects With Atopic Dermatitis (CTT-000386)

2012-2013: A Multiple-Dose (0.3%, 1%, And 3% [w/w]), Randomized, Blinded, Vehicle- And Active Comparator­ Controlled, Sequential Dose Cohorts, Multi-Center Trial To Assess The Safety, Pharmacokinetics, and Proof-Of­ Concept Efficacy Of Topical “Study Drug”, Applied Twice Daily For 28 Days, In Adult Subjects With Atopic Dermatitis (CTT-000365)

2012-2013: A Phase 1 Randomized, Observer-Blinded, Dose-Ranging Study To Evaluate The lmmunogenicity And Safety Of “Study Drug” In Healthy Young Adults With And Without Glucopyranosyl Lipid A-Stable Emulsion (GLA-SE) (CTT-000346)

2012-2013: A Phase I Randomized, Observer-Blinded, Dose-Ranging Study To Evaluate The lmmunogenicity And Safety Of “Study Drug” In Healthy Young Adults With And Without ISCOMATRIX™ (CTT-000344)

2012-2013: A Phase 2 Study Comparing Treatment With “Study Drug” In “Study Vehicle” And “Study Drug” In Subjects With Psoriasis Vulgaris (CTT-000355)

2012-2013: A Phase 2 Study Comparing Treatment With “Study Drug” Plus “Study Drug”, “Study Vehicle” And Ointment Vehicle In Subjects With Psoriasis Vulgaris (CTT-000354)

2011-2015: A Randomized, Double-Blind, Placebo Controlled Study To Assess The Efficacy Of “Study Drug” On Cardiovascular Risk (CTT-000317)

2011-2013: A Randomized, Double-Blind, Multicenter Study Of “Study Drug”, Assessing Psoriasis Area And Severity Index (PASI) Response And Maintenance Of Response In Subjects With Moderate To Severe Chronic Plaque-Type Psoriasis On Either A Fixed Dose Regimen Or On A Retreatment At Start Of Relapse Regimen (CTT-000313)

2011-2013: A Randomized, Double-Blind, Placebo Controlled, Multicenter Study Of “Study Drug” To Demonstrate Efficacy After Twelve Weeks Of Treatment, And To Assess The Safety, Tolerability And Long-Term Efficacy Up To One Year In Subjects With Moderate To Severe Chronic Plaque-Type Psoriasis (CTT-000311)

2011-2012: A Randomized, Double-Blind, Double Dummy, Multicenter Study To Assess The Safety, Tolerability And Long-Term Efficacy Of “Study Drug” In Subjects With Moderate To Severe Chronic Plaque-Type Psoriasis Who Are Partial Responders To Secukinumab (CTT-000327)

2011-2012: A Double Blinded, Prospective, Randomized, Vehicle Controlled Multi-Center Study Of Photodynamic Therapy With “Study Drug” In Patients With Acne Vulgaris (CTT-000282)

2011-2011: A Multicenter, Randomized, Active-Controlled, Open-Label, Parallel group, Pharmacokinetic And Pharmacodynamic Study To Access and Compare The Systemic Exposure Of “Study Drug” Topical Aerosol And “Study Drug” Ointment Under Maximal Use Conditions In Subjects With Plaque-Type Psoriasis (CTT-000291)

2010-2011: “Study Drug” Plus “Study Drug” Topical Suspension Compared To “Study Drug” In The Topical Suspension Vehicle, “Study Drug” In The Topical Suspension Vehicle And The Topical Suspension Vehicle Alone In Psoriasis Vulgaris (CTT-000250)

2010-2010: A Phase 2, Gender-Stratified, Double-Blind, Placebo-Controlled Study To Evaluate The Safety And lmmunogenicity Of A Two Vaccination Regimen With The “Study Drug” Vaccine System In Healthy Adults (CTT- 000214)

2009-2009: A Phase Three, Multicenter, Randomized, Double-Blind, Placebo Controlled Study To Evaluate The Efficacy Of The “Study Drug” Vaccine System (CTT-000176)

2009-2009: A Passive, Non-Invasive, Minimal Risk, Study Of Pressure Distribution Data In Healthy Adults Human Subjects When Lying Supine Or Sitting On Commercially Available Materials, With Or Without, Incorporated Rigid Surfaces (CTT-000205)

2009-2009: A Prospective, Single Arm, Phase I, Controlled Trial Evaluating The Functionality Of A “Study Device”, The Surgical Wound Management System (S.W.M.S), In Healthy Human Subjects (CTI-000173)

2008-2008: A Prospective, Bi Phasic, Feasibility Trial Evaluating The Safety Profile Of Multiple Dressing Design Configurations Under Negative Pressure On Healthy Subjects (CTI-000134)

2008-2008: A Prospective, Randomized, Controlled Trial Comparing “Study Device” Design Systems Under Negative Pressure On Healthy Subjects (CTI-000123)

2008-2008: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study To Compare The lmmunogenicity And Safety Of A Two Vaccination Regimen And One-Year Booster With An “Study Drug” Vaccine Patch At Two Different Doses In Normal Healthy Adults (CTI-000121)

2008-2008: Prospective, Controlled Study Evaluating “Study Device” Dressing Systems Under Negative Pressure On Healthy Subjects (CTI-000116)

2007-2008: A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study To Compare “Study Drug”, 1% To “Study Drug” 1%, And Both Active Treatments To A Vehicle Control In The Treatment Of Inflammatory Lesions Of Rosacea (CTI-000088)

2006-2007: Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study To Assess The lmmunogenicity And Safety Of “Study Drug” Application In Healthy Adults (CTI-000120)

2006-2007: A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study To Assess The lmmunogenicity And Safety Of “Study Drug” Application In Healthy Adults (CTI-000046)

Publications

2005
Cutaneous Tumors as the Initial Presentation of Non-T, Non-B, Nonmyeloid CD4+ CD56+ Hematolymphoid Malignancy in an Adolescent Boy; Fass, J MD; Tichy, E MD; Kraus, E  MD; Herrick,] MD; Ehsan, A MD; Peterson,] MD; Grimwood,  R MD; Pediatric

Dermatology; vol 22; p19; January 2005

Presentations of Original Papers 

2004
“Pigmented Pilomatricoma,” American Academy of Dermatology Annual Meeting, March 2004, Washington DC

2003
“From the Groin to the Finger, a Case of Ectopic Acanthosis Nigricans,” American Academy of Dermatology Annual Meeting, February 2003, San Francisco, California